

Study The Level Of Hs-Crp With Risk Factors Like Smoking, Hypertension And Diabetes Mellitus

Vikram Rathod*, Shiva Prasada T**, Jagdeesh B S*

*Senior Resident, Department Of General Medicine, Adichunchangiri Institute Of Medical Sciences B G Nagar,

**Assistant Professor, Department Of General Medicine, KIMS, Koppal, Karnataka, India

Abstract: Background: With the turn of the century, CVDs have become the leading cause of mortality in India. Objectives: To correlate the level of Hs-crp with risk factors smoking, hypertension and diabetes mellitus. Material & Methods: This cross sectional study was conducted on patients admitted in the Intensive cardiac Care Unit of Karnataka Institute of Medical Sciences, Hubli between November 2015 – January 2017. A total number of 110 patients were recruited for the study. Results: Out of the total 110 cases 78(70.9%) were male patients and 32(29.1%) female patients. Most of patients were in age group of 51-60 yrs (40%). In the study 18.2% had HTN, 22.7% had DM, 84.5% were smoking and consuming tobacco, 80% were consuming tobacco and 35.5% were alcoholics. In the study there was no significant association between hsCRP and Age, HTN, DM, Smoking, Alcohol and BMI. Hence the above mentioned factors were not affecting HSCRP. Conclusion: HSCRP can be included as one of the risk factor for CVD assessment and it can be used as screening in high risk individual for CVD assessment, which helps in primary prevention. [Rathod V Natl J Integr Res Med, 2020; 11(4):05-09]

Key Words: Hs-CRP, Smoking, Hypertension, Diabetes Mellitus, CVD

Author for correspondence: Dr. Shiva Prasada T, Senior Resident, Department of General Medicine, KIMS, Koppal, Karnataka - 583231 E-Mail: shivamalige5738@gmail.com Mobile: 9986738483

Introduction: Ischemic heart disease (IHD) and stroke constitute the majority of CVD mortality in India (83%), with IHD being predominant¹. The years of life lost attributable to CVD in India increased by 59% from 1990 to 2010 (23.2 million to 37 million)¹. The prevalence of IHD in 1960 in urban India was 2%, and increased 7-fold to ~14% by 2013^{2,3,4}. Similarly, it more than quadrupled in rural areas, from 1.7% to 7.4% between 1970 and 2013^{4,5}. The Macroeconomic Commission for Health estimated that the absolute number of IHD patients in India will increase from 36 million in 2005 to 62 million in 2015 (a ~70% increase)⁶.

Conventional risk factors in the Framingham risk score (FRS), such as age, male sex, hypercholesterolemia, hypertension, and smoking, account for most of the risk of CHD and have been the bedrock of risk assessment for decades. However, approximately one-third of individuals with 0 or 1 risk factor develop CHD^{7,8} and up to 40% of individuals with cholesterol levels below the population average die from CHD⁹.

We know atherosclerosis is most important cause of CHD, and Inflammation is the key mechanism in the pathogenesis of the different stages of atherosclerosis, from onset, progression of atheroma, plaque instability and rupture and restenosis following angioplasty^{10,11,12}.

Inflammatory biomarkers provide useful information on the inflammatory process of atherosclerosis; they act as a window into the

process of cell activation, recruitment of inflammatory cells and proliferation¹³. In recent decades, many studies have shown that CRP is associated with cardiovascular risk. This molecule has characteristics that make it a particularly attractive subject of study:

As a positive acute phase protein it is a marker of systemic inflammation that increases in response to various types of injury, particularly bacterial infections that function as inflammatory stimuli¹⁴.

Its production in the liver is induced mainly by interleukin-6 (IL-6) and, unlike other acute phase markers, its levels are relatively stable, with no significant diurnal variation, and can thus be accurately measured¹⁵.

During the 1990s high-sensitivity techniques were developed to detect lower serum CRP levels than by previous laboratory methods (down to 0.3 mg/l), known as high-sensitivity CRP (hs-CRP), and these techniques should be used when assessing the cardiovascular risk associated with the chronic vascular inflammation of atherosclerosis.

There is growing evidence that CRP is not merely a marker of inflammation, but also plays an active role in atherogenesis^{16,17}.

This study was conducted with the objective: To correlate the level of Hs-crp with risk factors smoking hypertension and diabetes mellitus.

Material & Methods: This cross sectional study was conducted on patients admitted in the Intensive cardiac Care Unit of Karnataka Institute of Medical Sciences, Hubli between November 2015 – January 2017. A total number of 110 patients were recruited for the study. Approval for the study was obtained from the KIMS, Hubli Ethics Committee. Informed consent was taken prior to inclusion in the study.

Inclusion Criteria: All patients with ACS
 1. STEMI
 2. NSTEMI
 3. Unstable angina

Sample Size: A total of 110 cases of ACS were included in the study during the period extending between December 2015 to January 2017. Sample size is calculated to be 110, considering the prevalence of ACS as 7.5% with confident interval of 95% and precession of 5%.

Exclusion Criteria: Patient with past CABG, Patient with PTCA, Patient with valvular heart disease. Patient with hepatic dysfunction, Patient with renal dysfunction creatinine > 1.5 mg / dL, Patient with collagen vascular disease, All patients with recent or ongoing infection, fever or inflammatory disorder & Recent trauma.

Method Of Collection Of Data: Patients present with h/o chest pain, shortness of breath, palpitation were taking thorough clinical history for previous h /o DM, HTN, IHD & measurement of blood pressure, & BMI , ECG and 2Decho was done, patients with clinical features ,ECG & 2Decho features suggestive of STEMI,NST-ACS, were selected for blood investigation which included Lipid profile, hsCRP, urea ,creatinine ,complete blood count and LFT,RA factor,and coronary angiography. patients with raised total count and abnormal LFT & Positive RA factor a features suggestive of inflammation were excluded from study . Informed written consent was taken from every patient.

Statistical Analysis: Data was entered into Microsoft excel data sheet and was analyzed using SPSS 22 version software. Categorical data was represented in the form of Frequencies and proportions. Continuous data was represented as mean and standard deviation. Independent t test or was used as test of significance to identify the mean difference between two quantitative variables. ANOVA (Analysis of Variance) was the test of significance to identify the mean difference between more than two groups for

quantitative data. Pearson correlation or Spearman’s correlation was done to find the correlation between two quantitative variables and qualitative variables respectively.

Results: 110 patients presenting with ACS who satisfied the inclusion criteria were enrolled in the study. The data both clinical as well as laboratory values were collected and then analysed accordingly. Out of the total 110 cases 78(70.9%) were male patients and 32(29.1%) female patients. 25(22.7%) patients were diabetic and 20(18.2%) patients were hypertensive on medication, 93 (84.5%) were smokers. By means of ECG out of 110 cases 81(73.6%) patients diagnosed as STEMI, 29(26.4%) were NST-ACS. On coronary angiography 56(52.8%) has SVD, 12(11.3%) has DVD, 20(18.9%) has TVD & 18(17.0%) has normal coronaries.

In the study majority of subjects were in the age group 51 to 60 years (40%), 20% were in the age group 41 to 50 years, 19.1% were in the age group 61 to 70 years, 16.4% were in the age group <40 years and 4.5% were in the age group >70 years. In the study 29.1% were females and 70.9% were males. Table 1

Table 1: Age Distribution Of Subjects In The Study

		Count	%
Age	<40 Years	18	16.4%
	41 to 50 Years	22	20.0%
	51 to 60 Years	44	40.0%
	61 to 70 Years	21	19.1%
	>70 Years	5	4.5%

In the study 18.2% had HTN, 22.7% had DM, 84.5% were smoking and consuming tobacco, 80% were consuming tobacco and 35.5% were alcoholics. Table 2

Table 2: Risk Factors Among Subjects

	Yes		No	
	Count	%	Count	%
HTN	20	18.2%	90	81.8%
DM	25	22.7%	85	77.3%
Smoking and Tobacco	93	84.5%	17	15.5%
Alcohol	39	35.5%	71	64.5%

In the study 18.2% had HTN, 22.7% had DM, 84.5% were smoking and consuming tobacco, 80% were consuming tobacco and 35.5% were alcoholics.

In the study there was no significant association between hsCRP and Age, HTN, DM, Smoking,

Alcohol and BMI. Hence the above mentioned factors were not affecting HSCRP. Table 3

Table 3: Association Between Hscrp And Age, HTN, DM, Smoking, Alcohol And BMI

		hsCRP						P value
		<1 mg%		1 to 3 mg%		>3 mg%		
		Count	%	Count	%	Count	%	
Age	<40 Years	8	16.7%	9	23.1%	1	4.3%	0.372
	41 to 50 Years	13	27.1%	6	15.4%	3	13.0%	
	51 to 60 Years	16	33.3%	16	41.0%	12	52.2%	
	61 to 70 Years	10	20.8%	6	15.4%	5	21.7%	
	>70 Years	1	2.1%	2	5.1%	2	8.7%	
HTN	Yes	10	20.8%	7	17.9%	3	13.0%	0.727
	No	38	79.2%	32	82.1%	20	87.0%	
DM	Yes	11	22.9%	10	25.6%	4	17.4%	0.755
	No	37	77.1%	29	74.4%	19	82.6%	
Smoking	Yes	39	81.2%	35	89.7%	19	82.6%	0.530
	No	9	18.8%	4	10.3%	4	17.4%	
Alcohol	Yes	18	37.5%	12	30.8%	9	39.1%	0.742
	No	30	62.5%	27	69.2%	14	60.9%	

In the study there was no significant difference in mean hsCRP levels with respect to risk factors HTN, DM, Smoking, Tobacco and Alcohol. Table 4

Table 4: Comparison Of Hscrp With Respect To Risk Factors

		hsCRP			P value
		Mean	SD	Median	
HTN	No	2.2	2.5	1.1	0.823
	Yes	2.3	2.4	1.2	
DM	No	2.2	2.5	1.2	0.745
	Yes	2.4	2.4	1.2	
Smoking	No	2.3	2.4	1.2	0.887
	Yes	2.2	2.9	.8	
Alcohol	No	2.3	2.2	1.2	0.908
	Yes	2.3	2.6	1.2	

Independent t test

Discussion: Several modifiable and non-modifiable factors such as HT, DM, smoking etc are recognized as major risk factors for CVD and aggressive correction of these play vital role in CVD prevention, because not all adverse CV events can be predicted or explained by these conventional risk factors, which limits our ability to accurately identify the individuals who are at “high risk” of developing CVD.

hsCRP And Age: Syed tanveer etal¹⁸ study found that patients with STEMI detected higher hs-CRP values (≥0.5 mg/dl) in older patients than young, study by Guruprasad etal¹⁹ had higher hsCRP in old age (1.8 ± 24mg/l) when compared to young

patient of (1.5 ± 1.1mg/l) ,Ramon Arroyo-Espliguero etal²⁰ study also support this where they concluded that hsCRP concentrations raise with increasing age.

In our study hsCRP increased with age, where mean hscrp was highest among those aged more than 70 yrs (mean hscrp 3.9) and lowest aged less than 40 yrs (mean hscrp 1.5) which is concordant with other studies.

hsCRP And Sex: Studies by Sharad Gupta etal²¹, McConnell JP etal²², have shown that the levels of hs-CRP are usually higher in women than men. In our study, men (mean hsCRP 2.4± 2.5mg/l) were found to have higher hsCRP levels as compared to women (mean hscrp 2.3 ± 2.4mg/l) which is not in concordant with other studies.

hsCRP And HTN: Study done by Bautista LE etal²³,i,e Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alfa) and essential hypertension and concluded TNF-alfa and IL-6 could be independent risk factors for HTN in apparently healthy subjects and CRP was not significantly associated with hypertension. Study done by sharad gupta etal²¹ also shows no significant correlation with hscrp and hypertension p-value 0.035. In our study we did not find significant association between elevated hsCRP levels and HTN p-value 0.727, which in concordant with other studies.

hsCRP And Diabetes Mellitus: Study conducted by Sharad et al²¹, p-value 0.08 (showed no statistical significance between hsCRP and Diabetes mellitus. In our study there was no statistical significance between non diabetic (mean hsCRP 2.48mg/l) and diabetes (2.4mg/l) with p-value 0.745 which is in concordance with other studies.

hsCRP And Smoking: Studies by Yanbaeva et al²⁴, Sharad Gupta et al²¹ and MA Mendall²⁵ which showed significant correlation between hsCRP and smoking. In our study, there was no significant correlation of hsCRP levels and smoking which is not in concordance with other studies.

Conclusion: It was concluded that hsCRP can be included as one of the risk factors for CVD assessment and it can be used as screening in high risk individuals for CVD assessment, which helps in primary prevention.

Acknowledgement: I would like to express my profound gratitude to all the participants for their co-operation and for their immense faith they reposed in me.

References:

- Institute of Health Metrics and Evaluation. GBD Compare 2010. <http://vizhub.healthdata.org/gbd-compare/>. Accessed April 30, 2014
- Mathur KS. Environmental factors in coronary heart disease. An epidemiological survey at Agra (India). *Circulation*. 1960;21:684-689.
- Praveen PA, Roy A, Anand K, Lakshmy R, Ruby G, Shah B, Reddy KS and Prabhakaran D. Rising prevalence of coronary heart disease (CHD) in urban Delhi, India—results from a repeat cross-sectional study. *Eur Heart J*. 2013;34(abstract suppl):470
- Gupta R. Recent trends in coronary heart disease epidemiology in India. *Indian Heart J*. 2008;60(2 suppl B):B4-18
- Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. *Heart*. 2008;94:16-26. doi: 10.1136/hrt.2007.132951
- Report of the National Commission on Macroeconomics and Health. New Delhi, India: Ministry of Health and Family Welfare, Government of India; 2005
- Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA* 2003;290:891-7.
- Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA* 2003;290:898-904
- Smith SC Jr. Current and future directions of cardiovascular risk prediction. *Am J Cardiol* 2006;97:28A-32A.
- Libby P. Changing concepts of atherogenesis. *J Intern Med*. 2000;247:349-58
- Liao JK. Beyond lipid lowering: the role of statins in vascular protection. *Int J Cardiol*. 2002;86:5-18
- Inoue T, Uchida T, Yaguchi I, et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. *Circulation*. 2003;107:1757-63
- Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. *Am J Cardiol*. 2003;91:9-13.
- Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. *Cleve Clin J Med*. 1989;56:126-30
- Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiologic applications. *Clin Chem*. 1997;43:52-8
- Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. *Am J Cardiol*. 2003;91:287-92.
- Inoue T, Kato T, Uchida T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. *J Am Coll Cardiol*. 2005;46: 239-45
- Syed tanver et al: clinical and angiographic correlation of high sensitivity C-reactive protein with acute ST elevation myocardial infarction; experimental and therapeutic medicine 12:4089-4098, 201
- Guruprasad, D, Rajasekhara, G, Subramanyam, P, V.L.N. Srinivasa Rao, V. Vanajakshamma, K. Latheef; High sensitivity C-reactive protein levels across spectrum and severity of coronary artery disease; *J Clin Sci Res* 2012;3:126-30
- Ramon Arroyo-Espliguero, Pablo Avanzas, Juan Cosin-Sales, Guillermo Aldama, Carmine Pizzi, Juan Carlos Kaski; C-reactive protein elevation and disease activity in patients with coronary

artery disease; European heart journal (2004) 25,401-408

21. Sharad Gupta et al; Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: An Indian perspective; indian heart journal 65(2013)357e367
22. Joseph P. McConnell*, Earl L. Branum, Karla V. Ballman, Susan A. Lagerstedt, Jerry A. Katzmann and Allan S. Jaffe; Clin Chem Lab Med 2002; 40(1):56–59
23. LE Bautista et al; Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- α) and essential hypertension Journal of Human Hypertension (2005) 19, 149–154
24. Dilyara G. Yanbaeva et al; Systemic Effects of Smoking; CHEST 2007; 131:1557–1566
25. Soman CR, Kutty VR, Safraj S, Vijayakumar K, Rajamohan K, Ajayan K; PROLIFE Study Group. All-cause mortality and cardiovascular mortality in Kerala state of India: results from a 5-year follow-up of 161,942 rural community dwelling adults. Asia Pac J Public Health. 2011;23:896–903. doi:10.1177/1010539510365100

Conflict of interest: None
Funding: None
Cite this Article as: Rathod V, Prasada S, S J. Study The Level Of Hs-CRP With Risk Factors Like Smoking, Hypertension And Diabetes Mellitus. Natl J Integr Res Med 2020; Vol.11(4): 05-09